Park Square has placed Laura Hamill as Independent Director at Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the Board of Directors (the “Board”) nominates healthcare executive Laura J. Hamill to be elected as a Class II director at the Company’s 2020 annual meeting of stockholders (the “Annual Meeting”).
![featured image](https://images.passle.net/fit-in/860x860/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/58a5d143b00e8110e83aa6e5/2020-06-15-14-10-53-441-5ee7816d5354890b54e7fb9d.png)